Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX

Simplify Asset Management Inc. purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 85,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,199,000. Simplify Asset Management Inc. owned approximately 0.13% of Celldex Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its position in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 881 shares during the period. Russell Investments Group Ltd. increased its position in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares in the last quarter. Headlands Technologies LLC acquired a new position in Celldex Therapeutics in the 2nd quarter valued at $125,000. Tower Research Capital LLC TRC raised its stake in Celldex Therapeutics by 289.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 5,387 shares during the last quarter. Finally, Overbrook Management Corp purchased a new position in Celldex Therapeutics in the 3rd quarter valued at $228,000.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $26.03 on Tuesday. The company has a market capitalization of $1.73 billion, a P/E ratio of -7.70 and a beta of 1.13. The company has a 50 day simple moving average of $26.24 and a 200-day simple moving average of $24.38. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $30.50.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. As a group, research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analyst Upgrades and Downgrades

CLDX has been the subject of a number of recent research reports. Mizuho assumed coverage on shares of Celldex Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $48.00 target price for the company. Barclays increased their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $62.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.10.

Insider Buying and Selling at Celldex Therapeutics

In other news, insider Richard M. Wright sold 49,298 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the completion of the transaction, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. This represents a 70.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.40% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.